Search Results - "Langslet, G"

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION) by Schernthaner, G., Durán-Garcia, S., Hanefeld, M., Langslet, G., Niskanen, L., Östgren, C. J., Malvolti, E., Hardy, E.

“…Aims To assess the efficacy and safety of adjunctive saxagliptin vs glimepiride in elderly patients with type 2 diabetes (T2D) and inadequate glycaemic…”
Get full text

Long term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials in childhood by Langslet, G, Bogsrud, M.P, Halvorsen, I, Retterstöl, K, Veieröd, M.B, Ose, L

Get full text

A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH) by Gaudet, D, Saheb, S, Bruckert, E, de Graaf, J, Langslet, G, Tardif, J.C, Bergheanu, S, Steinberg, A, Choi, Y.J, Martin, R, McWherter, C, Kastelein, J, Boudes, P

Get full text

Therapy with the thyroid hormone receptor agonist eprotirome in patients with familial hypercholesterolemia: a randomised, double blind, placebo-controlled study by Sjouke, B, Langslet, G, Ceska, R, Nicholls, S.J, Nissen, S.E, Öhlander, M, Ladenson, P.W, Olsson, A.G, Hovingh, G.K, Kastelein, J.J.P

Get full text

Effect of rosuvastatin therapy on carotid intima media thickness in children with familial hypercholesterolemia: Findings from the charon study by Braamskamp, M.J.A.M, Langslet, G, McCrindle, B.W, Cassiman, D, Francis, G.A, Gagné, C, Gaudet, D, Morrison, K.M, Wiegman, A, Turner, T, Miller, E, Raichlen, J.S, Martin, P.G, Stein, E.A, Kastelein, J.J.P

Get full text

Efficacy and safety of rosuvastatin in children aged 6–17 years with familial hypercholesterolemia: Findings from the charon study by Braamskamp, M, Langslet, G, McCrindle, B.W, Cassiman, D, Francis, G.A, Gagné, C, Gaudet, D, Morrison, K.M, Wiegman, A, Turner, T, Miller, E, Raichlen, J.S, Martin, P.G, Martin, P.D, Stein, E.A, Kastelein, J.J.P

Get full text

Safety, Tolerability, and Efficacy of Long-Term Administration of Amg 145: Preliminary Results From the Osler Study by Koren, M.J, Giugliano, R.P, Raal, F, Sullivan, D, Bolognese, M, Langslet, G, Civeira, F, Scott, R, Somaratne, R, Nelson, P, Liu, T, Xu, F, Wasserman, S.M, Sabatine, M.S

Get full text

Female patients with familial hypercholesterolemia have higher cholesterol burden at 19 and 30 years of age: Data from 12-years follow-up by Johansen, A.K., Bogsrud, M.P., Retterstøl, K., Langslet, G., Holven, K.B.

Get full text

P290 La canagliflozine montre des améliorations durables de la glycémie sur 104 semaines par comparaison avec le glimépiride chez des patients avec un diabète de type 2 sous metformine by Langslet, G, Leiter, L, Yoon, K, Arias, P, Xie, J, Balis, D, Millington, D, Ricci, L, Vercruysse, F, Canovatchel, W, Meininger, G

“…Introduction L’efficacité et la tolérance de la canagliflozine (CANA), un inhibiteur du co-transporteur sodium-glucose de type 2 ont été évaluées vs…”
Get full text

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials by RAAL, Frederick J, GIUGLIANO, Robert P, HUANG, Fannie, ALLEN XUE, ALBIZEM, Moetaz, SCOTT, Rob, STEIN, Evan A, SABATINE, Marc S, KOREN, Michael J, LANGSLET, Gisle, BAYS, Harold, BLOM, Dirk, ERIKSSON, Mats, DENT, Ricardo, WASSERMAN, Scott M

“…The purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp)(a) from a pooled analysis of 4 phase II trials. Lp(a), a…”
Get full text

Twenty-five percent of children with familial hypercholesterolemia treated with statins have compliance issues by Holven, K.B., Johansen, A.K., Bogsrud, M.P., Narverud, I., Langslet, G., Risstad, H., Retterstøl, K.

Get full text

P5272Concomitant heart failure (HF) and type 2 diabetes (T2D) - a deadly duo by Ofstad, A.P., Atar, D., Gullestad, L., Langslet, G., Johansen, O.E.

Get full text

The Cycle study: a prospective study on cholesterol levels during the menstrual cycle by Mulder, J, Balsrud, P, Schreuder, M, Van Vark-Van Der Zee, L C, Mulder, M T, Bogsrud, M P, Narverud, I, Retterstol, K, Langslet, G, Boersma, E, Holven, K B, Roeters Van Lennep, J E

“…Abstract Background Previous studies showed fluctuating lipid levels during the menstrual cycle in healthy women with normal cholesterol (nChol). Cycle-related…”
Get full text

Regional Variations In Alirocumab Dosing Patterns During An Open-Label Extension Study In Patients With Heterozygous Familial Hypercholesterolaemia by Langslet, G., Hovingh, G.K., Guyton, J.R., Baccara-Dinet, M.T., Letierce, A., Manvelian, G., Farnier, M.

Get full text

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) by Raal, Frederick J., MB BCh, MMed, PhD, Giugliano, Robert P., MD, SM, Sabatine, Marc S., MD, MPH, Koren, Michael J., MD, Langslet, Gisle, MD, Bays, Harold, MD, Blom, Dirk, PhD, MD, Eriksson, Mats, MD, Dent, Ricardo, MD, Wasserman, Scott M., MD, Huang, Fannie, MS, Xue, Allen, PhD, Albizem, Moetaz, MD, Scott, Rob, MD, Stein, Evan A., MD, PhD

“…Objectives The purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp)(a) from a pooled analysis of 4 phase II trials…”
Get full text

P5387LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients by Kastelein, J J P, Klausen, I C, Hovingh, G K, Heggen, E, Taub, R, Langslet, G

Get full text

Treat-to-target familial hypercholesterolemia (TTT-FH): A prospective study in adult patients with FH. Results after long term intensive lipid lowering treatment in a specialized lipid clinic by Arnesen, K., Randsborg, K., Mork, I., Thorwall, M., Ose, L., Svilaas, A., Langslet, G., Retterstøl, K.

Get full text

Treat-to-target familial hypercholesterolemia (TTT-FH): a prospective study in adult patients with FH. Women have many years off lipid lowering medication due to pregnancy by Arnesen, K., Randsborg, K., Mork, I., Thorwall, M., Ose, L., Svilaas, A., Langslet, G., Wium, C., Retterstøl, K.

Get full text

Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia by Svendsen, Karianne, Langslet, Gisle, Krogh, Henriette W., Brinck, Jonas, Klausen, Ib Christian, Stenehjem, Jo S., Holven, Kirsten B., Bogsrud, Martin P., Retterstøl, Kjetil

“…In familial hypercholesterolemia (FH), statin treatment should be considered from 8 to 10 years of age, but the prevalence of statin use among children is not…”
Get full text

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study by Karasik, Avraham, Lanzinger, Stefanie, Chia-Hui Tan, Elise, Yabe, Daisuke, Kim, Dae Jung, Sheu, Wayne H-H, Melzer-Cohen, Cheli, Holl, Reinhard W., Ha, Kyoung Hwa, Khunti, Kamlesh, Zaccardi, Francesco, Subramanian, Anuradhaa, Nirantharakumar, Krishnarajah, Nyström, Thomas, Niskanen, Leo, Linnemann Jensen, Majken, Hoti, Fabian, Klement, Riho, Déruaz-Luyet, Anouk, Kyaw, Moe H., Koeneman, Lisette, Vistisen, Dorte, Carstensen, Bendix, Halvorsen, Sigrun, Langslet, Gisle, Fazeli Farsani, Soulmaz, Patorno, Elisabetta, Núñez, Júlio

“…Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and…”
Get full text